Market Closed -
Nasdaq
16:00:00 2024-05-15 EDT
5-day change
1st Jan Change
39.21
USD
+2.46%
-2.37%
-22.49%
This article is reserved for members
Not a member ?
Free registration
Transcript : Ionis Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM
05-14
Transcript : Ionis Pharmaceuticals, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 10:30 AM
05-14
Wells Fargo Adjusts Ionis Pharmaceuticals Price Target to $82 From $85, Maintains Overweight Rating
05-08
MT
Ionis Pharmaceuticals Insider Sold Shares Worth $256,277, According to a Recent SEC Filing
05-07
MT
Transcript : Ionis Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
05-07
Ionis Pharmaceuticals Q1 Net Loss Widens as Revenue Falls
05-07
MT
Earnings Flash (IONS) IONIS PHARMACEUTICALS Posts Q1 Revenue $119M
05-07
MT
Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024
05-07
CI
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-07
CI
North American Morning Briefing : Stock Futures -2-
04-11
DJ
Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform
04-10
MT
North American Morning Briefing : Traders Await -2-
04-10
DJ
Oppenheimer Raises Ionis Pharmaceuticals' Price Target to $75 From $72, Maintains Outperform Rating
04-09
MT
Transcript : Ionis Pharmaceuticals, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 03:00 PM
04-08
Transcript : Ionis Pharmaceuticals, Inc. - Special Call
04-08
Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome
04-07
CI
Transcript : Ionis Pharmaceuticals, Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-20-2024 10:30 AM
03-20
Sector Update: Health Care Stocks Gain Premarket Wednesday
03-13
MT
Ionis Pharmaceuticals' Phase 2 Study of ION224 Achieves Liver Histologic Improvement; Shares Up
03-13
MT
Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial
03-13
RE
Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224
03-13
CI
Oppenheimer Adjusts Ionis Pharmaceuticals Price Target to $72 From $65, Maintains Outperform Rating
03-06
MT
Transcript : Ionis Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 11:10 AM
03-05
Ionis Pharmaceuticals, Inc. Announces Executive Changes
02-29
CI
Oppenheimer Adjusts Ionis Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating
02-26
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Companyâs products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
More about the company
Last Close Price
39.21
USD
Average target price
57.95
USD
Spread / Average Target
+47.79%
Consensus
1st Jan change
Capi.
-22.49% 5.72B +29.77% 49.46B +1.00% 42.58B +50.58% 42.49B -5.26% 29.09B +13.68% 26.61B -22.99% 18.64B +8.22% 13.16B +32.41% 12.55B -1.62% 11.98B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**